Robert C. Stein, PhD, MBBChir, FRCP, on ER-Positive HER2-Negative Early Breast Cancer: Test-Directed Chemotherapy
ASCO 2026
Robert C. Stein, PhD, MBBChir, FRCP, of the National Institute for Health Research University College London Hospitals Biomedical Research Centre, discusses the first results from the phase III randomized OPTIMA trial, which is comparing chemotherapy decisions made with the Prosigna (PAM50) gene expression test with standard treatment with estrogen receptor (ER)-positive, HER2-negative early breast cancer (Abstract 500).
The ASCO Post Staff
Colton Jones, MD, of The University of Texas at San Antonio, talks about the results of a global, multicenter analysis that sought to determine the safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the primary prevention of hepatocellular carcinoma (HCC) in a pan-etiology high-risk cohort (Abstract 10522).
Antonio Llombart-Cussac, MD, PhD, of Medica Scientia Innovation Research (MEDSIR), discusses the ongoing ADELA study, a double-blind, placebo-controlled, randomized phase III trial of elacestrant plus everolimus vs elacestrant plus placebo in patients with estrogen receptor (ER)-positive HER2-negative advanced breast cancer with ESR1-mutated tumors who experienced disease progression on endocrine therapy plus CDK4/6 inhibition (Abstract TPS1154).
ClinicalTrials.gov identifier: NCT06382948
The ASCO Post Staff
Elena Elimova, MD, Princess Margaret Cancer Centre, discusses the efficacy in PD-L1 subgroups of zanidatamab plus chemotherapy with or without tislelizumab as a first-line regimen for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (Abstract 4010).
The ASCO Post Staff
Siddhartha Yadav, MBBS, MD, of Mayo Clinic Rochester, talks about a real-world evaluation of germline pathogenic variants in cancer predisposition genes in unselected South Asian women with breast or ovarian cancer (Abstract 10513).
Laura Alder, MD, of Duke University Medical Center, highlights emerging data discussed in the meeting’s oral abstract session on small cell lung cancer, including increased toxicity without efficacy benefit from concurrent chemoradiation and immunotherapy, the intracranial activity of tarlatamab-dlle, and early data for a SEZ6-targeting antibody-drug conjugate.
